Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andre Gauri

Clinical Cardiac Electrophysiology Grand Rapids, MI Medical Doctor

NPI 1215928684 CMS profile 326784

2900 Bradford St Ne, Grand Rapids, MI 49525

Open in the dashboard

General payments

$125,512

342 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$367,134 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Andre Gauri of Grand Rapids, MI is reported in the CMS Open Payments database as having received $125,512 across 342 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $367,134 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,362 59
2024 General $5,068 37
2023 General $11,191 37
2022 General $34,529 57
2021 General $23,186 36
2020 General $31,521 54
2019 General $12,655 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andre Gauri
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Andre Gauri were reported at $7,362. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Andre Gauri Clinical Cardiac Electrophysiology median Middle half National median
2019 $12,655 $2,361 $585–$8,260 $163
2020 $31,521 $993 $247–$4,351 $114
2021 $23,186 $1,185 $326–$4,739 $132
2022 $34,529 $2,073 $554–$6,789 $149
2023 $11,191 $2,568 $759–$8,159 $160
2024 $5,068 $2,557 $703–$7,403 $164
2025 $7,362 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Atricure, Inc. $48,012 69 payments
  2. Medtronic Vascular, Inc. $28,644 67 payments
  3. Medtronic, Inc. $24,660 74 payments
  4. iRhythm Technologies, Inc. $8,507 9 payments
  5. Boston Scientific Corporation $7,145 23 payments
  6. Abbott Laboratories $4,712 49 payments
  7. Biosense Webster, Inc. $2,108 24 payments
  8. Medical Device Business Services, Inc. $700 1 payment
  9. Acutus Medical, Inc. $200 2 payments
  10. Janssen Pharmaceuticals, Inc $175 7 payments
  11. Other $649 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $58,925 45 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $36,050 20 payments
  3. Food and Beverage $16,282 237 payments
  4. Travel and Lodging $11,741 38 payments
  5. Grant $2,500 1 payment
  6. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. ATRICLIP LAA EXCLUSION SYSTEM $24,171 21 payments
  2. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $15,252 23 payments
  3. Arctic Front Ablation $13,321 25 payments
  4. Arctic Front Ablation $9,112 6 payments
  5. EPI-SENSE GUIDED COAGULATION SYS $7,843 24 payments
  6. ZIO Patch Cardiology/Vascular Diseases $6,400 3 payments
  7. Carto 3 $2,694 23 payments
  8. General - Therapies $1,875 2 payments
  9. ZIO Patch Cardiology/Vascular Diseases $1,750 1 payment
  10. ISOLATOR SURGICAL ABLATION SYSTEM $1,575 2 payments
  11. Other $18,582 186 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,822

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,076,724

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

52.7%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 558 $728,128
Xarelto Rivaroxaban Brand 196 $235,977
Multaq Dronedarone Hcl Brand 21 $42,982
Dofetilide Generic 103 $30,270
Flecainide Acetate Generic 195 $11,677
Metoprolol Succinate Generic 323 $11,606
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 95 $4,907
Amiodarone Hcl Generic 152 $3,570
Propafenone Hcl Er Propafenone Hcl Brand 12 $3,260
Sotalol Sotalol Hcl Brand 67 $2,146

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$73,143

Medicare's payments for the services billed

Medicare patients

659

Average age 76

Services billed

1,636

293 women, 366 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 63%
Heart failure 53%
Ischemic heart disease 51%
Arthritis 51%
Chronic kidney disease 38%
Diabetes 36%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

342 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record